Stay updated on Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial

Sign up to get notified when there's something new on the Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The changes appear to be cosmetic updates to formatting and minor textual tweaks; no core content like eligibility criteria, interventions, outcomes, or enrollment numbers was added or removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-03T12:31:06.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    33 days ago
    Change Detected
    Summary
    Core content updated with a new diagnosis term and new revision, plus an operating-status notice; a prior cancer term and old version are removed.
    Difference
    1%
    Check dated 2025-10-05T16:44:45.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    Terminology updated from 'Plasma cell myeloma' to 'Multiple myeloma' and version bumped from v3.0.2 to v3.1.0.
    Difference
    0.1%
    Check dated 2025-09-28T09:59:28.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    Revision updated from v3.0.1 to v3.0.2; the only other deletion is a minor UI element ('Back to Top') and does not affect core content.
    Difference
    0.1%
    Check dated 2025-09-14T00:11:43.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.
    Difference
    0.1%
    Check dated 2025-09-06T21:09:27.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The web page has been updated to include new facility names and locations, as well as additional resources related to various cancers, while removing outdated location terms and some specific cancer resources. Notably, the names of drugs such as dabrafenib and trametinib have been added, indicating a focus on recent advancements in cancer treatment.
    Difference
    6%
    Check dated 2025-08-30T15:31:05.000Z thumbnail image

Stay in the know with updates to Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial page.